Eutilex Co.,Ltd. Logo

Eutilex Co.,Ltd.

Develops T-cell and antibody immunotherapies for cancer and autoimmune diseases.

263050 | KO

Overview

Corporate Details

ISIN(s):
KR7263050007
LEI:
Country:
South Korea
Address:
서울특별시 금천구 가산디지털1로 58 408호 (가산동, 에이스한솔타워), 서울특별시
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Eutilex Co., Ltd. is a biotechnology company focused on the research and development of breakthrough immunotherapeutics for incurable diseases, particularly cancer and autoimmune disorders. The company's core activities are centered around three proprietary technology platforms: T-cell therapy, antibody therapy, and CAR-T cell therapy. Its pipeline includes adoptive T-cell therapies, such as 4-1BB cytotoxic T-lymphocytes (CTL), and immunomodulatory antibody therapeutics designed to act as immune checkpoint activators, stimulating T-cells to enhance anti-tumor immune responses. Eutilex's approach is based on selecting novel targets that effectively enhance or suppress human immune functions to treat diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.3 MB
2025-07-18 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.1 KB
2025-06-30 00:00
Share Issue/Capital Change
주식매수선택권부여에관한신고
Korean 15.0 KB
2025-05-22 00:00
Major Shareholding Notification
[기재정정]임원ㆍ주요주주특정증권등소유상황보고서
Korean 28.0 KB
2025-05-22 00:00
Major Shareholding Notification
[기재정정]임원ㆍ주요주주특정증권등소유상황보고서
Korean 28.3 KB
2025-05-22 00:00
Major Shareholding Notification
[기재정정]임원ㆍ주요주주특정증권등소유상황보고서
Korean 28.5 KB
2025-05-22 00:00
Major Shareholding Notification
[기재정정]임원ㆍ주요주주특정증권등소유상황보고서
Korean 28.3 KB
2025-05-22 00:00
Major Shareholding Notification
[기재정정]주식등의대량보유상황보고서(일반)
Korean 116.7 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 959.6 KB
2025-05-13 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.7 KB
2025-05-13 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.0 KB
2025-05-13 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.2 KB
2025-05-13 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.0 KB
2025-05-13 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 112.9 KB
2025-05-08 00:00
Regulatory News Service
단일판매ㆍ공급계약체결
Korean 10.1 KB

Automate Your Workflow. Get a real-time feed of all Eutilex Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Eutilex Co.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Eutilex Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

MicroAd,Inc. Logo
Data-driven marketing tech providing DSP and SSP solutions for digital advertising.
Japan
9553
Microwave Chemical Co., Ltd. Logo
Innovating chemical and metal processing with an eco-friendly microwave platform.
Japan
9227
MindWalk Holdings Corp. Logo
AI-powered biotherapeutics firm offering end-to-end antibody discovery and engineering services.
United States of America
HYFT
Minerva Neurosciences, Inc. Logo
A clinical-stage biopharma developing treatments for central nervous system (CNS) diseases.
United States of America
NERV
A think tank providing research, consulting, and ICT solutions to public & private sectors.
Japan
3636
Modalis Therapeutics Corporation Logo
Develops epigenome editing therapies for genetic muscular, heart, and CNS disorders.
Japan
4883
Model Solution Co., Ltd. Logo
One-stop prototyping & low-volume production for IT, electronics, and medical hardware.
South Korea
417970
Modus Therapeutics Holding AB Logo
Developing sevuparin, a polysaccharide for sepsis, septic shock, and chronic inflammation.
Sweden
MODTX
Moleculin Biotech, Inc. Logo
Developing therapies for hard-to-treat tumors (like AML) and viruses.
United States of America
MBRX
Molecure S.A. Logo
Develops first-in-class small molecule drugs for oncology and inflammatory/fibrotic diseases.
Poland
MOC

Talk to a Data Expert

Have a question? We'll get back to you promptly.